Globus Medical (NYSE:GMED) Director David Davidar Sells 25,000 Shares

Globus Medical, Inc. (NYSE:GMED) Director David Davidar sold 25,000 shares of Globus Medical stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director owned 510,175 shares in the company, valued at $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Globus Medical Stock Performance

Shares of GMED stock traded up $4.30 on Tuesday, reaching $82.60. 1,482,503 shares of the company’s stock traded hands, compared to its average volume of 1,392,665. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The company has a market capitalization of $11.21 billion, a P/E ratio of 19.21, a price-to-earnings-growth ratio of 1.65 and a beta of 0.95. The business’s 50 day moving average price is $86.08 and its two-hundred day moving average price is $88.20.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. During the same quarter in the previous year, the company posted $0.68 earnings per share. Globus Medical’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Research analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Piper Sandler reiterated an “overweight” rating on shares of Globus Medical in a report on Tuesday. Barclays lifted their price target on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Needham & Company LLC boosted their target price on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Wells Fargo & Company lowered their target price on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Sanctuary Advisors LLC grew its stake in Globus Medical by 2.3% in the first quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock valued at $570,000 after purchasing an additional 151 shares in the last quarter. SBI Securities Co. Ltd. grew its stake in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Globus Medical by 2.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company’s stock valued at $375,000 after purchasing an additional 170 shares in the last quarter. Parallel Advisors LLC grew its stake in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.